2017 American Transplant Congress
The Cumulative United States Experience with Transplants (Txs) from Living Donors (LDs): 140,156 LD Txs in 28 Years.
Background/Purpose: Solid organ txs from LDs provide better outcome results than from DDs. We analyzed the cumulative US LD tx experience since UNOS inception. The…2017 American Transplant Congress
The Relationship Between Frailty and Decreased Physical Performance with Death on the Kidney Transplant Waiting List.
Background: Frailty and decreased physical performance are associated with poor outcomes after kidney transplant. Less is known about their relationship with pre-transplant outcomes. The aim…2017 American Transplant Congress
Outcomes of Hand Assisted Laparoscopic Right Donor Nephrectomy, Single Center Experience.
Transplant Surgery, The Ohio State Wexner Medical Center, Columbus, OH
Right donor nephrectomy,especially when conducted laparoscopically,has not been accepted by most transplant surgeons because of the consequent short right renal vein and the possible increased…2017 American Transplant Congress
Release of HMGB1 in Serum and Urine of Brain-Death Donors Is Associated with Delayed Graft Function (DGF) of the Kidney.
Delayed kidney graft function (DGF) following a kidney transplant is associated with worse graft survival and higher rejection risk. Risk factors for DGF have been…2017 American Transplant Congress
Analysis of Outcomes in High Risk Kidney Transplants.
Kidney and Pancreas Transplantation, NewYork-Presbyterian Weill Cornell Medical Center, New York, NY
Background: The new kidney allocation system implemented in 12/2014 utilizes estimated post-transplant survival scores (EPTS) and kidney donor profile index (KDPI) to optimize recipient survival…2017 American Transplant Congress
Rituximab Desensitization (DES) and Alemtuzumab Induction Significantly Reduced EBV Viremia and Post-Transplant Lymphoproliferative Disorder (PTLD) in HLA-Sensitized (HS) Kidney Transplant Patients.
Background: PTLD is a serious complication in KTx pts and is usually associated with EBV infection. Recent studies showed that rituximab treatment prior to Tx…2017 American Transplant Congress
Circulating Donor-Specific Memory B Cells (mBc) Discriminates Kidney Transplant Patients with Histological Lesions of ABMR in Absence of Circulating DSA.
Chronic (c)ABMR is a main cause of immune-mediated kidney allograft loss. For its diagnosis, specific histological lesions together with presence of circulating donor-specific alloantibodies (DSA)…2017 American Transplant Congress
Avoidance or Reduction of Rituximab Might Improve Clinical Outcomes in ABO-Incompatible Renal Transplantation: Advantages and Disadvantages of Rituximab.
BACKGROUNDPretransplant desensitization with rituximab has contributed to drastic improvements in ABO-incompatible renal transplantation (ABO-I). However, ABO-I outcomes are still worse than those of ABO-identical or…2017 American Transplant Congress
KDPI Usefulness in Spain: A Comparison with Classical ECD/SCD.
Kidney donor shortage requires an expansion in selection criteria and objective tools to minimize discarded organs. Easy donor pretx variables such as age, standard/expanded criteria…2017 American Transplant Congress
Post-Transplant Urinary Transglutaminase 2 Is a Potent Biomarker to Predict Kidney Allograft Inflammation or Fibrosis.
Transglutaminase type 2 (TG2) is an extracellular matrix crosslinking enzyme with a pivotal role in kidney fibrosis. We tested the hypothesis that quantification of urinary…
- « Previous Page
- 1
- …
- 344
- 345
- 346
- 347
- 348
- …
- 531
- Next Page »
